Ibrutinib is active both in treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, including those with unmutated immunoglobulin heavy chain variable region (IGHV) genes and TP53 disruption.1-3 The acquisition of BTK or PLCg2 gene mutations conferring resistance, supports the existence of clonal evolution also under ibrutinib treat ment.4-8 Whilst it is well described that subclonal TP53 mutations undergo a positive clonal selection following chemoimmunotherapy (CIT),9-11 being the main driver of treatment failure, recent studies have suggested that this might not be the case under ibrutinib.
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia / Cafforio, L.; Raponi, S.; Cappelli, L. V.; Ilari, C.; Soscia, R.; de Propris, M. S.; Mariglia, P.; Rigolin, G. M.; Bardi, A.; Peragine, N.; Piciocchi, A.; Arena, V.; Mauro, F. R.; Cuneo, A.; Guarini, A.; Foa, R.; Del Giudice, I.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 107:1(2022), pp. 334-337. [10.3324/haematol.2020.263715]
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
Cafforio L.;Raponi S.;Cappelli L. V.;Ilari C.;Soscia R.;de Propris M. S.;Peragine N.;Mauro F. R.;Guarini A.;Foa R.;Del Giudice I.
2022
Abstract
Ibrutinib is active both in treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, including those with unmutated immunoglobulin heavy chain variable region (IGHV) genes and TP53 disruption.1-3 The acquisition of BTK or PLCg2 gene mutations conferring resistance, supports the existence of clonal evolution also under ibrutinib treat ment.4-8 Whilst it is well described that subclonal TP53 mutations undergo a positive clonal selection following chemoimmunotherapy (CIT),9-11 being the main driver of treatment failure, recent studies have suggested that this might not be the case under ibrutinib.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cafforio_Treatment-with-ibrutinib_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
4.74 MB
Formato
Adobe PDF
|
4.74 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
